Omnicell, Inc.
NASDAQ:OMCLMedical - Healthcare Information Services
-$0.58 today
- Market cap
- $1.59B
- Beta
- 0.96
- P/E (TTM)
- 84.1
- EPS (TTM)
- $0.45
Volume 0.34M
Average 0.57M
OMCL EBITDA Margin
EBITDA as a percentage of revenue.
Omnicell, Inc.NASDAQ: OMCL
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 11.4%
EBITDA Margin was 11.4% in Q1 FY2026, up 6.8 pp from a year earlier. On a trailing-twelve-month basis it was 10.2%, down 0.9 pp year over year. Over 3 fiscal years it widened by 1.1 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 6 analysts of 18.4% for the fiscal year ending Dec 2026, up from 8.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 11.4%+3.4 pp QoQ
- Last fiscal yearDec 2025
- 8.6%-2.2 pp YoY
- LTMMar 2026
- 10.2%-0.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +6.8 pp | +4.4 pp | -2.4 pp |
| 1 year | -2.2 pp | +9.8 pp | +12.0 pp |
| 3 years | +1.1 pp | +7.6 pp | +6.5 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 8.6%
- Year-over-year change
- -2.2pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.6% | -2.2pp |
| FY2024 | 2024-12-31 | 10.8% | +3.8pp |
| FY2023 | 2023-12-31 | 7.0% | -0.5pp |
| FY2022 | 2022-12-31 | 7.5% | -7.8pp |
| FY2021 | 2021-12-31 | 15.3% | — |
EBITDA Margin vs competitors
How OMCL compares with its peers on the latest reported figures
- OMCL's LTM Mar 2026 EBITDA Margin of 10.2% is the 3rd highest of the 11 companies compared; the peer median is 5.3%.
- Its year-over-year change of -0.9 pp is the 10th highest of 11, against a peer median of +6.4 pp.
- Over three fiscal years its change of +1.1 pp compares with a peer median of +20.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 22.0% | +0.5 pp | +14.6 pp | |
| LTM Jun 2026 | 18.4% | -0.8 pp | -0.5 pp | |
| LTM Mar 2026 | 10.2% | -0.9 pp | +1.1 pp | |
| LTM Jun 2026 | 9.7% | +2.2 pp | +4.5 pp | |
| LTM Apr 2026 | 8.6% | +10.7 pp | +57.9 pp | |
| LTM Sep 2026 | 6.1% | +10.9 pp | +25.5 pp | |
| LTM Mar 2026 | 4.6% | -1.1 pp | -5.5 pp | |
| LTM Mar 2026 | 2.3% | +1.0 pp | +6.1 pp | |
| LTM Mar 2026 | 0.2% | +15.0 pp | +69.9 pp | |
| LTM Mar 2026 | -7.7% | +82.2 pp | +350.1 pp | |
| LTM Sep 2026 | -15.2% | +50.2 pp | +42.4 pp | |
| Peer median (excluding OMCL) | 5.3% | +6.4 pp | +20.1 pp | |
Competitors are the stored peer set for OMCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.13B | 1.3B | 1.15B | 1.11B | 1.18B |
| Cost of Revenue | 577.37M | 706.96M | 647.18M | 641.24M | 676.8M |
| Gross Profit | 554.65M | 588.99M | 499.93M | 471M | 508.04M |
| Gross Margin | 49.0% | 45.4% | 43.6% | 42.3% | 42.9% |
| Research & Development | 75.72M | 104.97M | 93.29M | 90.41M | 87.74M |
| Selling, General & Admin | 389.43M | 486.34M | 425.97M | 380.25M | 408.64M |
| Operating Expenses | 465.15M | 591.31M | 519.26M | 470.67M | 496.38M |
| Depreciation & Amortization | 84.93M | 99.17M | 95.56M | 89.76M | 86.63M |
| EBITDA | 173.33M | 96.85M | 79.98M | 119.87M | 101.87M |
| EBITDA Margin | 15.3% | 7.5% | 7.0% | 10.8% | 8.6% |
| Operating Income | 89.51M | (2.32M) | (19.33M) | 337K | 11.67M |
| Operating Margin | 7.9% | -0.2% | -1.7% | 0.0% | 1.0% |
| Interest Income | 0 | 0 | 14.76M | 24.9M | 11.9M |
| Interest Expense | 22.39M | 130K | 0 | 4.53M | 3.91M |
| Other Income / Expenses | (23.5M) | (130K) | (779K) | 25.26M | (340K) |
| Income Before Tax | 66.01M | (2.45M) | (20.11M) | 25.59M | 11.33M |
| Pre-Tax Margin | 5.8% | -0.2% | -1.8% | 2.3% | 1.0% |
| Income Tax Expense | (11.84M) | (8.1M) | 263K | 13.06M | 9.27M |
| Net Income | 77.85M | 5.65M | (20.37M) | 12.53M | 2.05M |
| Net Margin | 6.9% | 0.4% | -1.8% | 1.1% | 0.2% |
| EPS (Basic) | 1.79 | 0.13 | (0.45) | 0.27 | 0.04 |
| EPS (Diluted) | 1.62 | 0.12 | (0.45) | 0.27 | 0.04 |
| Weighted Avg Shares | 43.48M | 44.4M | 45.21M | 46.05M | 45.97M |
| Weighted Avg Shares (Diluted) | 47.94M | 45.89M | 45.21M | 46.26M | 46.36M |
Omnicell, Inc.
NASDAQ:OMCL
Intrinsic Alpha fair value
Locked
Current Price
$34.66
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.